|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
By this method, the expression levels of MGMT mRNA in six human glioma cell lines and 12 human brain tumor tissues from surgical specimens were determined.
|
1518162 |
1992 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Southern analysis of EcoRI-digested DNA probed with MGMT cDNA revealed no amplification, rearrangement or deletions of the MGMT gene in any of the glioma cell lines.
|
1893534 |
1991 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The basal promoter in glioma cells with minimal MGMT expression, however, which is 75% unmethylated, was much less accessible, and the basal promoter in nonexpressing cells, which is 50% unmethylated, was entirely inaccessible to restriction enzymes.
|
7523853 |
1994 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of the O6-methylguanine DNA methyltransferase (MGMT) gene in human glioma cell lines is strongly associated with resistance to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea.
|
8006031 |
1994 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MGMT expression correlated exclusively with ACNU resistance in all glioma cell lines examined (p = 0.0002).
|
10678554 |
1999 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Drug-resistance genes messenger ribonucleic acid (mRNA) expressions were investigated in drug-resistant human glioma cell lines derived from U87MG and 46 frozen samples of retrospectively examined neuroepithelial tumors (12 low grade neuroepithelial tumors, 16 Grade III gliomas, 11 glioblastomas, and 7 other malignant neuroepithelial tumors such as medulloblastomas and primitive neuroectodermal tumors) by RT-PCR with the specific primers for O6-methylguanine DNA methyltransferase (MGMT), multidrug-resistance gene 1 (MDR1), multidrug-resistance-associated protein (MRP), and glutathione-S-transferase-pi (GST-pi).
|
10894369 |
2000 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
|
11070098 |
2000 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The dose-intensified BG and BCNU therapy produced significant growth delays of glioma xenografts in MGMT-P140K-transplanted mice, extending the tumor doubling time by >40 days.
|
14707273 |
2003 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Finally, the MGMT methylation status determined in the initial glioma tumor did not correlate with the clinical response to temozolomide when this drug was administered as treatment for relapses (P = 0.729).
|
15297393 |
2004 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
O6-Methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, is one of the implicated factors in glioma chemoresistance.
|
16033832 |
2005 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Ninety-three patients with anaplastic glioma were analyzed for MGMT protein expression by immunohistochemistry.
|
16033832 |
2005 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation specific polymerase chain reaction (MSP) was used to determine the methylation status the promoters for p16/(INK4a), MGMT, p73, and RARbeta within glioma tissue and plasma.
|
16466990 |
2006 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
|
16899598 |
2006 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.
|
17192931 |
2006 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue.
|
17260000 |
2007 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Thus, we propose that the study using the transformed astrocyte cells would be useful for identifying the mechanisms underlying MGMT regulation in tumor and for the development of rational drug combination in glioma therapies.
|
17547775 |
2007 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation of the O(6)-methyguanine-DNA methyltransferase (MGMT) gene promoter in gliomas has been reported to be a useful predictor of the responsiveness to temozolomide (TMZ).
|
17564708 |
2008 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
|
17721049 |
2007 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also found a significant correlation between the extent of NF-kappaB activation and MGMT expression in the glioma cell lines and the human glial tumors tested and showed that it was independent of MGMT promoter methylation.
|
17875738 |
2007 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using the population based San Francisco Adult Glioma study, we evaluated associations between XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT Ile143Val polymorphisms with glioma risk among white cases (n = 441 to 453) and controls (n = 487 to 526).
|
17898525 |
2007 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MGMT promoter methylation and low expression of MGMT-encoded protein are frequently observed in low-grade gliomas and anaplastic oligodendroglial tumours.
|
17906460 |
2007 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While treatment with 5azadC downregulated hTERT and upregulated MGMT expression in two glioma cell lines, there was no change in the expression of these two genes in the normal cell line.
|
18021753 |
2008 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PsPD has a clinical impact on chemotherapy-treated GBM, as it may express the glioma killing effects of treatment and is significantly correlated with MGMT status.
|
18445844 |
2008 |
|
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
|
18556773 |
2008 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, to correctly establish MGMT expression in the tumor, which could be informative of glioma sensitivity to alkylating agents, exclusion of non-neoplastic brain components from analysis is required.
|
18580490 |
2008 |